Extraordinary arousal from semi-comatose state on zolpidem

A young semi-eomatose male patient was investigated using 99mTc hexamethyl-propylene amine oxime (99mTc HMPAO) brain single photon emission computed tomography (SPECf) before and after administration of the gamma-aminobutyric acid (GABA) agonist zolpidem. It was observed that 15 minutes after application of the drug the patient awoke from his semi-eomatose condition and remained awake for the next 3 - 4 hours. When drug action subsided he returned to his semi-eomatose state. Brain SPECf before drug application showed large hypo-active areas in certain parts of the brain. Brain SPECf after drug application showed a generalised cortical activation relative to the cerebellum and a marked and amplified activation of the areas that were hypo-active before drug application

Comparison of 68Ga-PSMA-11 PET/CT findings between different races in patients with low-risk prostate cancer

https://drive.google.com/file/d/1SZzO-jWrUWhk5KNoj2LviVDCRHCdf4c-/view?usp=sharinghttps://drive.google.com/drive/folders/1HCEseoxJvj0J_2MUrcaLivB933vZiDbM?usp=sharinghttps://drive.google.com/drive/folders/1RnVnA-vitkYBezFlKRpz9oTbWMm1gqgS?usp=sharin

Development and prospects of dedicated tracers for the molecular imaging of bacterial infections

Bacterial infections have always been, and still are, a major global healthcare problem. For accurate treatment it is of utmost importance that the location(s), severity, type of bacteria, and therapeutic response can be accurately staged. Similar to the recent successes in oncology, tracers specific for molecular imaging of the disease may help advance the patient management. Chemical design and bacterial targeting mechanisms are the basis for the specificity of such tracers. The aim of this review is to provide a comprehensive overview of the molecular imaging tracers developed for optical and nuclear identification of bacteria and bacterial infections. Hereby we envision that such tracers can be used to diagnose infections and aid their clinical management. From these compounds we have set-out to identify promising targeting mechanisms and select the most promising candidates for further development.The Netherlands Organisation for Scientific Research (NWO; STW BGT 11272).http://pubs.acs.org/bchb201

[68 Ga]Ga-FAPi PET/CT vs [18F]F-FDG PET/CT in various cancers: Initial experience

https://drive.google.com/file/d/1XJSXXwXb9eK56-UgDlrw69lIXleOi6IC/view?usp=sharinghttps://drive.google.com/drive/folders/1KrqkKx5LQG9uPrY6_gsr7jjg7XEVv_To?usp=sharinghttps://drive.google.com/drive/folders/1fpqwRHsic5hXdQnMQKRDXvm-_DzlLUfS?usp=sharin

Editorial: Work-based assessment: A critical element of specialist medical training

No Abstrac

Development and Prospects of Dedicated Tracers for the Molecular Imaging of Bacterial Infections

Imaging- and therapeutic targets in neoplastic and musculoskeletal inflammatory diseas

PET/CT scanning with a high HIV/AIDS prevalence

Positron emission tomography (PET) with [F-18]-fluoro-deoxy-glucose (FDG) has a well established and growing role in the management of most lymphomas. The interpretation of FDG PET scans in HIV positive patients is however challenging. This is largely due to scan changes giving a higher likelihood of false positive studies from both the direct effects of HIV and its treatment, and related to secondary HIV-related pathology. There is currently a need for further clinical research to evaluate to contribution of FDG PET in the management of HIV positive patients with lymphoma. In this paper existing studies related to FDG PET scanning in HIV positive patients will be reviewed, and potential pitfalls will be identified. These pitfalls can be avoided to some extent by the interpreter having a good clinical knowledge of the individual patients’ condition, and an awareness of known scintigraphic patterns that can occur in these patients. PET remains a sensitive tool for the localisation of pathology, however when the exact nature of lesions has a direct bearing on patient management lesions need to be biopsied where possible. FDG PET can be particularly useful for the characterisation of brain lesions suspected to be related to primary central nervous system lymphoma